LABCORP HOLDINGS INC (LH)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for LH
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| LH | President of Novartis US | 47 | ["Master’s in Health Economics and Pharmacoeconomics","Postgraduate Degree in Pharmaceutical Marketing","MBA from ESADE","Advanced Management Program at Harvard Business School","Master of Science in Chemical Engineering","Bachelor of Science in Chemistry","Extensive experience in the healthcare industry","Proven track record of leading large, complex organizations across the U.S. and Europe"] | ["Audit Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Victor Bulto has served as a director of the Company since December 1, 2025, and a member of the Audit Committee since April 2026. Mr. Bulto is President of Novartis US and a member of the Novartis Executive Committee since April 2022. With more than two decades at Novartis, he has held senior roles across major therapeutic areas and several geographies, including President of U.S. Pharmaceuticals, Head of U.S. Alcon Pharmaceuticals, and Head of the Neuroscience Franchise for Region Europe. Mr. Bulto holds a Master s in Health Economics and Pharmacoeconomics and a Postgraduate Degree in Pharmaceutical Marketing from Universitat Pompeu Fabra. He earned his MBA from ESADE and completed the Advanced Management Program at Harvard Business School. He also holds a Master of Science in Chemical Engineering and a Bachelor of Science in Chemistry from Institut Qu mic de Sarri in Spain.